Back to resultsAssessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Primary Purpose
Colorectal Neoplasms
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
SU011248
Sponsored by
About this trial
This is an interventional treatment trial for Colorectal Neoplasms
Eligibility Criteria
Inclusion Criteria: Metastatic colorectal cancer Failed selected cancer therapies in the past. Exclusion Criteria: Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than bevacizumab.
Sites / Locations
Outcomes
Primary Outcome Measures
Anti-tumor efficacy
Secondary Outcome Measures
Tumor control survival safety
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00077987
Brief Title
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Official Title
A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab
Study Type
Interventional
2. Study Status
Record Verification Date
October 2005
Overall Recruitment Status
Completed
Study Start Date
December 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
April 2005 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Pfizer
4. Oversight
5. Study Description
Brief Summary
Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Neoplasms
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
84 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
SU011248
Primary Outcome Measure Information:
Title
Anti-tumor efficacy
Secondary Outcome Measure Information:
Title
Tumor control survival safety
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Metastatic colorectal cancer
Failed selected cancer therapies in the past.
Exclusion Criteria:
Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than bevacizumab.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
We'll reach out to this number within 24 hrs